Targeted inhibition of autophagy in hepatic stellate cells by hydroxychloroquine: An effective therapeutic approach for the treatment of liver fibrosis
Liver International · 2024
DOI: 10.1111/liv.15915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Li-Shuang Hou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Hydroxychloroquine, Hepatic Stellate Cells, Autophagy, Liver Cirrhosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanxi Province.
Abstract (Originalsprache)
Background and Purpose Liver fibrosis is a wound‐healing reaction which is the main cause of chronic liver diseases worldwide. The activated hepatic stellate cell (aHSC) is the main driving factor in the development of liver fibrosis. Inhibiting autophagy of aHSC can prevent the progression of liver fibrosis, but inhibiting autophagy of other liver cells has opposite effects. Hence, targeted inhibition of autophagy in aHSC is quite necessary for the treatment of liver fibrosis, which prompts us to explore the targeted delivery system of small molecule autophagy inhibitor hydroxychloroquine (HCQ) that can target aHSC and alleviate the liver fibrosis.
Methods
The delivery system of HCQ@retinol‐liposome nanoparticles (HCQ@ROL‐LNPs) targeting aHSC was constructed by the film dispersion and pH‐gradient method. TGF‐β‐induced HSC activation and thioacetamide (TAA)‐induced liver fibrosis mice model were established, and the targeting ability and therapeutic effect of HCQ@ROL‐LNPs in liver fibrosis were studied subsequently in vitro and in vivo.
Results
HCQ@ROL‐LNPs have good homogeneity and stability. They inhibited the autophagy of aHSC selectively by HCQ and reduced the deposition of extracellular matrix (ECM) and the damage to other liver cells. Compared with the free HCQ and HCQ@LNPs, HCQ@ROL‐LNPs had good targeting ability, showing enhanced therapeutic effect and low toxicity to other organs.
Conclusion
Construction of HCQ@ROL‐LNPs delivery system lays a theoretical and experimental foundation for the treatment of liver fibrosis and promotes the development of clinical therapeutic drugs for liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
- Key Laboratory of Pharmacology of the State Administration of Traditional Chinese Medicine, Fourth Military Medical University, Xi'an, China.
- Department of Drug Quality Management, Shannxi Institute for Food and Drug Control, Xi'an, China.
ORCID-Profile: Bang-Le Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanxi Province
Zitieren
APA
Hou, L. S., Zhai, X. P., Zhang, Y. W., Xing, J. H., Li, C., Zhou, S. Y., Zhu, X. H., & Zhang, B. L. (2024). Targeted inhibition of autophagy in hepatic stellate cells by hydroxychloroquine: An effective therapeutic approach for the treatment of liver fibrosis. Liver International. https://doi.org/10.1111/liv.15915
Vancouver
Hou LS, Zhai XP, Zhang YW, Xing JH, Li C, Zhou SY, et al. Targeted inhibition of autophagy in hepatic stellate cells by hydroxychloroquine: An effective therapeutic approach for the treatment of liver fibrosis. Liver International. 2024. doi:10.1111/liv.15915
BibTeX
@article{Hou2024,
author = {Hou, Li-Shuang and Zhai, Xiao-Pei and Zhang, Yao-Wen and Xing, Jie-Hua and Li, Chen and Zhou, Si-Yuan and Zhu, Xiao-Hong and Zhang, Bang-Le},
title = {Targeted inhibition of autophagy in hepatic stellate cells by hydroxychloroquine: An effective therapeutic approach for the treatment of liver fibrosis},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15915}
}
EUVIMED